AstraZeneca is reportedly in discussions with Bristol Myers Squibb for a potential megamerger that could be valued at approximately $250 billion, according to sources familiar with the matter. The Financial Times reported on Sunday that the British pharmaceutical giant has been exploring options for a significant consolidation in recent months. While the precise terms and structure of such a deal remain unclear, it could lead to the formation of a pharmaceutical powerhouse.
Neither AstraZeneca nor Bristol Myers Squibb have confirmed these discussions. Reuters was unable to immediately verify the report, with AstraZeneca declining to comment and Bristol Myers Squibb not responding to inquiries outside of regular business hours. This potential deal comes about twelve years after AstraZeneca successfully fended off an acquisition attempt by its larger American rival, Pfizer.
This news emerges despite AstraZeneca's CEO, Pascal Soriot, recently stating that the company does not need large-scale mergers and acquisitions (M&A) to sustain growth. During AstraZeneca's Q2 2026 earnings call, Soriot emphasized the company's strong pipeline, with an aggregate success rate near 60%, as the basis for this confidence. The company reported total revenue of $15,384 million for Q2 2026, up 6.41% year-over-year, and adjusted earnings per share of $2.63, beating estimates by 6.28%. This stance contrasts with previous reports, such as one from 2020 where AstraZeneca had contacted Gilead Sciences about a potential merger, which ultimately did not materialize.
